Related Experiment Video
Updated: Oct 9, 2026
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Rationale for the development of recombinant human CC10 as a therapeutic for inflammatory and fibrotic disease
1Claragen, Incorporated, 387 Technology Drive, College Park, MD 20742, USA. apilon@claragen.com
Abstract:
CC10/uteroglobin is a remarkable protein whose physiological roles have only recently been explored in vivo. Both transgenic mice that have been rendered deficient and humans that have been characterized as deficient in this protein exhibit tendencies toward inflammatory, fibrotic, and oncologic disease, demonstrating the potential of the protein as a therapeutic agent. The protein itself is an excellent candidate for clinical development because of its inherent physical properties. It is relatively small, resistant to proteases, stable to extremes of heat and pH, and can be produced by recombinant methods. The physiological roles of this multifunctional protein continue to be uncovered as research progresses in vitro, in animals, and eventually in humans. The pathways through which CC10 mediates its effects, its receptors, and other family members will be a rich source of exciting research, as well as potential diagnostic and therapeutic agents. This paper is an introductory, noncomprehensive review of some of the scientific and medical rationale in support of CC10-based therapies in selected clinical applications.
Insights
Uteroglobin (CC10) deficiency is linked to inflammatory, fibrotic, and oncologic diseases. This protein shows therapeutic potential due to its stability and recombinant production capabilities for future treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Medical Science
Background:
- CC10/uteroglobin's physiological roles are increasingly understood through in vivo studies.
- Deficiency in CC10/uteroglobin is associated with inflammatory, fibrotic, and oncologic conditions.
- These findings highlight CC10/uteroglobin's potential as a therapeutic agent.
Purpose of the Study:
- To review the scientific and medical rationale for CC10-based therapies.
- To explore CC10/uteroglobin's potential in selected clinical applications.
- To discuss the protein's properties and ongoing research into its functions.
Main Methods:
- Review of in vitro, animal, and human studies on CC10/uteroglobin.
- Analysis of CC10/uteroglobin's physical and biochemical properties.
- Exploration of genetic deficiency models (transgenic mice, human studies).
Main Results:
- CC10/uteroglobin deficiency correlates with increased risk of inflammatory, fibrotic, and oncologic diseases.
- The protein exhibits favorable characteristics for clinical development: small size, protease resistance, stability, and recombinant production feasibility.
- Ongoing research continues to reveal the multifaceted roles of CC10/uteroglobin.
Conclusions:
- CC10/uteroglobin holds significant promise as a therapeutic agent for various diseases.
- Further research into CC10/uteroglobin pathways, receptors, and family members may yield new diagnostic and therapeutic strategies.
- CC10-based therapies are supported by substantial scientific and medical rationale for clinical application.
